samedi 28 juin 2014

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC

For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said.

Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC

Aucun commentaire:

Enregistrer un commentaire